AI Article Synopsis

  • - The study examined the link between specific autoantibodies (AT1R-AAs and ETAR-AAs) and left ventricular remodeling (LVR) in patients who experienced a myocardial infarction (heart attack), highlighting how these antibodies affect treatment outcomes.
  • - Conducted on 131 patients treated for ST-segment-elevation myocardial infarction, researchers found a significant prevalence of these autoantibodies in those who developed LVR, with 39% of patients with LVR being seropositive for AT1R-AAs.
  • - The findings indicate that AT1R-AAs not only correlate with LVR but also serve as a risk factor for future serious heart-related events, suggesting potential targets for improving

Article Abstract

Background: The left ventricular remodeling (LVR) process has limited the effectiveness of therapies after myocardial infarction. The relationship between autoantibodies activating AT1R-AAs (angiotensin II receptor type 1-AAs) and ETAR-AAs (autoantibodies activating endothelin-1 receptor type A) with myocardial infarction has been described. Among patients with ST-segment-elevation myocardial infarction, we investigated the relationship between these autoantibodies with LVR and subsequent major adverse cardiac events.

Methods And Results: In this prospective observational study, we included 131 patients with ST-segment-elevation myocardial infarction (61±11 years of age, 112 men) treated with primary percutaneous coronary intervention. Within 48 hours of admission, 2-dimensional transthoracic echocardiography was performed, and blood samples were obtained. The seropositive threshold for AT1R-AAs and ETAR-AAs was >10 U/mL. Patients were followed up at 6 months, when repeat transthoracic echocardiography was performed. The primary end points were LVR, defined as a 20% increase in left ventricular end-diastolic volume index, and major adverse cardiac event occurrence at follow-up, defined as cardiac death, nonfatal re-myocardial infarction, and hospitalization for heart failure. Forty-one (31%) patients experienced LVR. The prevalence of AT1R-AAs and ETAR-AAs seropositivity was higher in patients with versus without LVR (39% versus 11%, <0.001 and 37% versus 12%, =0.001, respectively). In multivariable analysis, AT1R-AAs seropositivity was significantly associated with LVR (odds ratio [OR], 4.66; =0.002) and represented a risk factor for subsequent major adverse cardiac events (OR, 19.6; =0.002).

Conclusions: AT1R-AAs and ETAR-AAs are associated with LVR in patients with ST-segment-elevation myocardial infarction. AT1R-AAs are also significantly associated with recurrent major adverse cardiac events. These initial observations may set the stage for a better pathophysiological understanding of the mechanisms contributing to LVR and ST-segment-elevation myocardial infarction prognosis.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11010093PMC
http://dx.doi.org/10.1161/JAHA.123.032672DOI Listing

Publication Analysis

Top Keywords

myocardial infarction
20
receptor type
12
angiotensin receptor
8
endothelin-1 receptor
8
left ventricular
8
relationship autoantibodies
8
autoantibodies activating
8
patients st-segment-elevation
8
st-segment-elevation myocardial
8
major adverse
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!